HYPM.Y logo

HyperaOTCPK:HYPM.Y Stock Report

Market Cap US$3.0b
Share Price
US$4.74
My Fair Value
US$5.15
8.0% undervalued intrinsic discount
1Y-7.2%
7D-0.7%
Portfolio Value
View

HYPM.Y Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Hypera S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hypera
Historical stock prices
Current Share PriceR$4.74
52 Week HighR$5.92
52 Week LowR$2.64
Beta0.39
1 Month Change-2.32%
3 Month Change36.67%
1 Year Change-7.19%
3 Year Change-35.48%
5 Year Change-31.22%
Change since IPO-67.29%

Recent News & Updates

Recent updates

Shareholder Returns

HYPM.YUS PharmaceuticalsUS Market
7D-0.7%-2.2%0.8%
1Y-7.2%-10.8%13.7%

Return vs Industry: HYPM.Y exceeded the US Pharmaceuticals industry which returned -10% over the past year.

Return vs Market: HYPM.Y underperformed the US Market which returned 14.8% over the past year.

Price Volatility

Is HYPM.Y's price volatile compared to industry and market?
HYPM.Y volatility
HYPM.Y Average Weekly Movement10.2%
Pharmaceuticals Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.1%

Stable Share Price: HYPM.Y has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: HYPM.Y's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199910,481Breno Pires de Oliveirawww.hypera.com.br

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand.

Hypera S.A. Fundamentals Summary

How do Hypera's earnings and revenue compare to its market cap?
HYPM.Y fundamental statistics
Market capUS$3.00b
Earnings (TTM)US$145.67m
Revenue (TTM)US$1.20b
20.3x
P/E Ratio
2.5x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HYPM.Y income statement (TTM)
RevenueR$6.70b
Cost of RevenueR$2.92b
Gross ProfitR$3.78b
Other ExpensesR$2.97b
EarningsR$810.61m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Aug 07, 2025

Earnings per share (EPS)1.28
Gross Margin56.39%
Net Profit Margin12.10%
Debt/Equity Ratio79.3%

How did HYPM.Y perform over the long term?

See historical performance and comparison

Dividends

4.5%
Current Dividend Yield
84%
Payout Ratio

Does HYPM.Y pay a reliable dividends?

See HYPM.Y dividend history and benchmarks
When do you need to buy HYPM.Y by to receive an upcoming dividend?
Hypera dividend dates
Ex Dividend DateJun 30 2025
Dividend Pay DateJan 08 2027
Days until Ex dividend23 days
Days until Dividend pay date534 days

Does HYPM.Y pay a reliable dividends?

See HYPM.Y dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/21 12:19
End of Day Share Price 2025/07/21 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hypera S.A. is covered by 28 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andréa AznarBB Banco de Investimento S.A.
Robert Ford AguilarBofA Global Research
Marcio OsakoBradesco S.A. Corretora de Títulos e Valores Mobiliários